Aug 22, 2015
AngioScore and USCI Japan, a prominent provider of medical devices in Japan for several years together to achieve this critical important milestone read article . Japan is a major market opportunity for AngioScore, second carried out by the United States the number of cardiovascular procedures on an annual basis. ‘We are very pleased reached this critically important milestone,’said Thomas R. Trotter, president and CEO of AngioScore. ‘Very few small medical device companies will ever have access to the Japanese market as the nation’s high performance standards and strict quality control. Than 10 of the result of many years of effort with our marketing partner USCI Japan, and is a testament to the hard work and dedication of many people in both organizations. Van Zandt Van Zandt, USCI Japan CEO, added, ‘Japanese doctors are very interested in the use of the best medical technology and the AngioSculpt represents a truly innovative advancement to improve patient quality of life, this is our first MHLW / PMDA submission under Japan’s new Pharmaceutical Affairs Law. We are with the Japanese government to help progress on patient access to new therapies satisfied. We see this as a milestone in collaboration between government and industry, a concrete example of new speed and efficiency in the Japanese healthcare system of authorization. ‘ – Added Trotter: ‘done every year with more than 180,000 interventional procedures in Japan believe that believe that the more rapidly AngioSculpt a significant market presence as 10th 000 AngioSculpt catheters are used worldwide and have an excellent track record in the treatment. Both coronary and peripheral arterial disease. ‘.
Important milestone.anese Approval for AngioSculpt Scoring Balloon CatheterAngioScore, a developer of novel angioplasty catheters for use in the treatment of cardiovascular diseases, announced today that its flagship product, the AngioSculp Scoring Balloon Catheter has approval import Japan obtained Ministry of Health, Labour and Welfare for the interventional treatment of coronary artery disease in this country. Read the rest of this entry »